Page last updated: 2024-11-06

web 2086

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WEB 2086: structure given in first source; PAF antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65889
CHEMBL ID280164
CHEBI ID92490
SCHEMBL ID94167
MeSH IDM0149056

Synonyms (74)

Synonym
HMS3268N16
BRD-K28115081-001-01-9
gtpl1860
gtpl1859
[3h]web 2086
3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-4-yl]-1-(morpholin-4-yl)propan-1-one
[3h]apafant
web-2086
de-081
apafant
brn 4302553
web 2086bs
web 2086
3-(4-(2-chlorophenyl)-9-methyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-2-yl)-1-(4-morpholinyl)-1-propanone
apafanto [inn-spanish]
morpholine, 4-((4-(2-chlorophenyl)-9-methyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-1-oxopropyl)-
apafantum [inn-latin]
4-(3-(4-(o-chlorophenyl)-9-methyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine
apafant [usan:inn]
PDSP2_000659
PDSP1_000669
web2086
apafant (jan/usan/inn)
D01652
105219-56-5
NCGC00092377-01
OPREA1_587188
CHEMBL280164 ,
web 2086 bs
web-2086-bs
L001111
FT-0662248
3-[4-(2-chloro-phenyl)-9-methyl-6h-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-1-morpholin-4-yl-propan-1-one(web 2086)
3-[4-(2-chloro-phenyl)-9-methyl-6h-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-1-morpholin-4-yl-propan-1-one(web2086)
bdbm50000714
3-[4-(2-chloro-phenyl)-9-methyl-6h-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-1-morpholin-4-yl-propan-1-one
NCGC00092377-02
NCGC00183135-01
NCGC00092377-03
unii-j613ni05sv
apafantum
apafanto
j613ni05sv ,
dtxcid5028900
dtxsid5048974 ,
tox21_113429
tox21_113594
cas-105219-56-5
apafant [mart.]
apafant [mi]
apafant [jan]
apafant [inn]
apafant [usan]
SCHEMBL94167
NCGC00092377-04
tox21_113594_1
4-[3-[4[(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a]diazepin-2-yl]-1-oxopropyl]morpholine
3-(4-(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)-1-morpholinopropan-1-one
AKOS024457059
4-[3-[4[(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a]diazepin-2-yl]-1-oxopropyl]]morpholine
J-001361
SR-01000945084-1
sr-01000945084
CHEBI:92490
web2086, >=98% (hplc)
1-propanone, 3-[4-(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-;1-propanone, 3-[4-(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-
(e)-3-(4-(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)-1-morpholinopropan-1-one
HMS3677G14
HMS3413G14
Q27074478
CS-0029365
3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]-1-morpholin-4-ylpropan-1-one
MS-28313
HY-108634

Research Excerpts

Overview

WEB 2086 is a novel PAF-acether antagonist. Its pharmacological action in man has only been preliminarily defined. It is a potent inhibitor of rabbit platelet aggregation and ATP secretion induced by 370 nM PAF.

ExcerptReferenceRelevance
"WEB 2086 is a PAF antagonist that has been shown experimentally to improve survival after hemorrhagic shock."( Effect of WEB 2086 on leukocyte adherence in response to hemorrhagic shock in rats.
Cheung, LY; Childs, EW; Miller, JL; Moncure, M; Smalley, DM, 2000
)
1.43
"Oral WEB 2086 is a potent and specific inhibitor of cutaneous and platelet responses to PAF in man."( Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.
Barnes, PJ; Chung, KF; Griffith, S; Hayes, JP; Ridge, SM, 1991
)
0.96
"WEB 2086 is a potent inhibitor of rabbit platelet aggregation and ATP secretion induced by 370 nM PAF."( The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin, K; Hong, T; Levy, JV, 1989
)
1
"WEB 2086 is a novel PAF-acether antagonist, whose pharmacological action in man has only been preliminarily defined. "( Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation.
Adamus, WS; Brecht, HM; Frey, G; Heuer, H; Meade, CJ, 1988
)
2.02

Actions

ExcerptReferenceRelevance
"WEB 2086 reduced the increase in vascular permeability induced by platelet-activating factor (PAF-acether) in rat abdominal skin. "( Inhibition by WEB 2086, a PAG-acether antagonist of oedema and peritonitis induced by zymosan in rats.
Damas, J; Nguyen, TP; Remacle-Volon, G,
)
1.93

Treatment

WEB 2086 treatment did not significantly affect platelet aggregation stimulated by ADP or arachidonic acid (AA) The treatment prevented the increase of AH after the OA exposure. Treatment promoted the attachment of supernumerary spermatozoa to fertilized and unfertilized oocytes.

ExcerptReferenceRelevance
"WEB 2086 treatment did not significantly affect platelet aggregation stimulated by ADP or arachidonic acid (AA)."( Inhibition of platelet-activating factor fails to limit ischemia and reperfusion-induced myocardial damage.
Black, SC; Driscoll, EM; Lucchesi, BR, 1992
)
1
"The WEB 2086 treatment also prevented the increase of AH after the OA exposure (PC200 Hist; 2.82 +/- 0.09 before the challenge 2.80 +/- 0.07 and 2.75 +/- 0.09 24 hr and 5 days after, respectively."( [Involvement of platelet activating factor (PAF) in ovalbumin antigen-induced late asthmatic response and increase of airway hyperresponsiveness in a guinea pig experimental model of asthma].
Arima, M; Makino, S; Sagara, H; Terashi, Y; Yukawa, T, 1991
)
0.76
"WEB 2086 treatment also promoted the attachment of supernumerary spermatozoa to both fertilized and unfertilized oocytes."( Role of spermatozoal platelet-activating factor in fertilization.
Geissler, FT; Henderson, WR; Kuzan, FB, 1990
)
1
"WEB 2086 pretreatment of the neutrophil or WEB 2086 coincubation with PAF, but not WEB 2086 pretreatment of the HUVE cell monolayers, significantly inhibited (65 to 80%) neutrophil migration."( Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular species.
Carolan, EJ; Casale, TB, 1990
)
1
"In WEB 2086-treated rats, blood pressure fell from a baseline mean of 181 +/- 13.0 to 125 +/- 23 mm Hg after 4 hours, a fall of 28%."( Platelet activating factor and one-kidney, one clip hypertension.
Burton, DL; Cotter, JL; Sturm, MJ; Vandongen, R, 1990
)
0.79
"Treatment with WEB 2086 on the day of implantation (Day 4) by intraperitoneal injection or instillation into the uterus only did not significantly reduce the implantation rate and neither did treatment after implantation (Days 5-8)."( Platelet-activating factor-antagonists reduce implantation in mice at low doses only.
O'Neill, C, 1995
)
0.63
"Treatment with WEB 2086 attenuated the pulmonary leak during the entire reperfusion period but improved cardiac output only during the first 30 min of reperfusion and had no effect on other hemodynamic variables."( Platelet-activating factor mediates pulmonary macromolecular leak following intestinal ischemia-reperfusion.
Carter, MB; Garrison, RN; Wead, WB; Wilson, MA, 1996
)
0.63
"Treatment with WEB 2086, alone or in combination with Zileuton, did not inhibit LPS-mediated hepatic neutrophil infiltration or liver injury, as assessed by histologic evaluation and increases in plasma alanine aminotransferase activity."( Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Bailie, MB; Fink, GD; Pearson, JM; Roth, RA, 1997
)
0.64
"Treatment with WEB 2086 significantly (P < 0.05) reduced tracheal microvascular leakage (FMLP 76.3 +/- 13.1 WEB 2086/FMLP 31.4 +/- 3.7 micrograms/g trachea) as did ICI198615 (FMLP 69.8 +/- 11.5 ICI198615/FMLP 30.0 +/- 5.7)."( Role of platelet activating factor, leukotrienes and polymorphs in the FMLP induced increase in microvascular leakage in rabbit trachea.
Berend, N; Matheson, MJ; McClean, MA; Rynell, AC, 1997
)
0.64
"Treatment with WEB 2086 also attenuated a decrease in leukocyte deformability, increase in size of neutrophils, and CD11b expression by circulating neutrophils."( Role of platelet-activating factor in alveolar septal injury associated with experimentally induced pneumonic pasteurellosis in calves.
Evanson, OA; Fagliari, JJ; McClenahan, DJ; Weiss, DJ, 2000
)
0.65
"Pretreatment with WEB 2086 (5 x 10(-7) M) warded off nearly all damage caused by hypoxia/reoxygenation."( The role of platelet-activating factor (PAF) antagonists and nitric oxide in cardiac actions of PAF. Electrophysiological and morphological study.
Balogh, I; Kecskeméti, V, 2000
)
0.63
"Pretreatment with WEB 2086 (10 mg/kg i.p.), meclizine (30 mg/kg i.p.) or both increased the survival rate from 15 to 57, 68 and 87%, respectively."( Interference of azelastine with anaphylaxis induced by ovalbumin challenge in actively sensitized rats.
Bozza, PT; Castro-Faria-Neto, HC; Cordeiro, RS; Lima, MC; Martins, MA; Silva, AR; Silva, PM; Vargaftig, BB, 1992
)
0.61
"Pretreatment with WEB 2086 prevented IC-induced hemoconcentration but not neutropenia."( Inhibition of immune complex-induced enteropathy by three different platelet-activating factor receptor antagonists.
Bishara, SM; Bloch, KJ; Bloch, M; Ng, BP, 1991
)
0.6
"Pretreatment with WEB 2086 (2 mg/kg iv) or SDZ 63-675 (10 mg/kg iv) blocks PAF-induced vasoconstriction and significantly attenuates the clearance of FITC-Dx 150 evoked by PAF, producing mean clearance values of 2,164 +/- 604 and 3,648 +/- 262 nl.2 h-1.g-1 respectively."( Resistance and exchange microvessels are modulated by different PAF receptors.
Durán, WN; Tomeo, AC, 1991
)
0.6
"Treatment with WEB 2086 (3 mg/kg intravenously) 30 min before and 3 hr after the exposure suppressed LAR clearly without affecting the IAR."( [Involvement of platelet activating factor (PAF) in ovalbumin antigen-induced late asthmatic response and increase of airway hyperresponsiveness in a guinea pig experimental model of asthma].
Arima, M; Makino, S; Sagara, H; Terashi, Y; Yukawa, T, 1991
)
0.62
"Treatment with WEB 2086 (10 mg/kg ip) either 20 min before or 30 min after endotoxin injection significantly reduced lung injury at 2 h after endotoxin (leak index: control 0.74 +/- 0.03, endotoxin 1.79 +/- 0.14, endotoxin + pretreated WEB 1.23 +/- 0.09, endotoxin + posttreated WEB 1.21 +/- 0.13)."( Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury.
Chang, SW; Fernyak, S; Voelkel, NF, 1990
)
0.86

Toxicity

ExcerptReferenceRelevance
" No clinically relevant drug related adverse events or changes in laboratory or vital parameters such as blood pressure, heart rate, respiratory rate and ECG were observed."( Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Adamus, WS; Birke, FW; Brecht, HM; Heuer, HO; Kempe, ER, 1991
)
0.28
" Nevertheless, no clinically significant drug-related effects on vital and laboratory parameters or obvious drug-dependent adverse reactions were observed."( Safety, tolerability, and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects.
Adamus, WS; Brecht, HM; Heuer, H; Meade, CJ, 1989
)
0.49

Pharmacokinetics

ExcerptReferenceRelevance
" Apafant (WEB 2086, CAS 105219-56-5), a novel synthetic PAF receptor antagonist, was administered to a total of 101 healthy volunteers within 5 studies to investigate its pharmacologic activity, pharmacokinetic behaviour and safety profile."( Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Adamus, WS; Birke, FW; Brecht, HM; Heuer, HO; Kempe, ER, 1991
)
0.68

Compound-Compound Interactions

ExcerptReferenceRelevance
" Treatment of rats with WEB, alone or in combination with Zileuton, did not attenuate ANIT-induced liver injury as assessed by increases in plasma alanine aminotransferase or gamma-glutamyl transferase activities."( Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity.
Bailie, MB; Fink, GD; Pearson, JM; Roth, RA, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
" The failure of a receptor blocker of leukotrienes to moderate disease expression suggests either a less important role for these chemicals in AOM or an insufficient bioavailability of the specific MK 571 inhibitor."( Expression of acute otitis media after receptor blockade of platelet activating factor, thromboxane, and leukotrienes in the chinchilla.
Alper, CM; Burckart, GJ; Diven, WF; Doyle, WJ; Evans, RW; Jaffe, R, 1998
)
0.3
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Selective PAF, TXA2 and 5HT antagonists (WEB 2086, sulotroban and MCI-9042) clearly inhibited both the shape change and the aggregation induced by the appropriate agonist. In each case the effect of the antagonist was to move the dose-response curve to the right.

ExcerptRelevanceReference
" Propranolol (1 mg/kg) produced a small shift to the left and atropine (1 mg/kg) and the serotonin antagonist, methysergide (1 mg/kg), produced a small shift to the right in the bombesin dose-response curve."( Bombesin-induced bronchoconstriction in the guinea pig: mode of action.
Barnes, PJ; Belvisi, MG; Stretton, CD, 1991
)
0.28
" When platelets were pretreated with either BDZR ligand, and then exposed to various concentrations of WEB 2086, there was no alteration of the dose-response relationship of the hetrazepine on PAF-induced aggregation, as reflected by threshold concentration, ED50, or maximum inhibition seen with WEB 2086."( The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin, K; Hong, T; Levy, JV, 1989
)
0.49
" Incubation of eosinophils with the PAF-antagonist WEB 2086 led to a parallel shift of the dose-response curve to the right, indicating a competitive antagonism."( Stimulation of degranulation from human eosinophils by platelet-activating factor.
Barnes, PJ; Chung, KF; Dent, G; Kroegel, C; Venge, P; Yukawa, T, 1989
)
0.53
" WEB 2086 shifted the Paf dose-response curve rightwards in a parallel manner."( Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Benveniste, J; Bidault, J; Delautier, D; Hirafuji, M; Keraly, CL; Korth, R, 1989
)
1.47
" The dose-response curve for fall in BP was shifted to the right by one order of magnitude."( Platelet-activating factor (Paf) antagonist, WEB 2086, protects against Paf-induced hypotension in Macaca fascicularis.
Antoniw, JW; Izumi, T; Piper, PJ; Stanton, AW, 1989
)
0.54
" For these studies, airway responsiveness was determined from slopes of carbachol dose-response curves (DRC) performed at base line (prechallenge) and 2 h after Ascaris suum antigen challenges in the following three protocols: 1) antigen challenge alone (control trial), 2) WEB-2086 (1 mg/kg iv) given 30 min before antigen challenge (WEB pretreatment), and 3) WEB-2086 given 2 h after antigen challenge, immediately before the postchallenge DRC (WEB posttreatment)."( A PAF antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep.
Abraham, WM; Sielczak, MW; Solèr, M, 1989
)
0.28
" A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])."( The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma.
Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994
)
0.72
" PAF injected into the peritoneal cavity induced a bell-shaped dose-response curve of EB extravasation in both strains of mouse."( Differential sensitivity of mouse strains to platelet activating factor-induced vasopermeability and mortality: effect of antagonists.
Jancar, S; Russo, M; Vásquez-Bravo, YL, 1993
)
0.29
" Taking into account that dosing amount of Fe-TPAA was limited due to its toxicity, the effective ROS scavenging may not have been obtained."( [Effects of reactive oxygen species scavenger and platelet activating factor receptor antagonist on accelerated nephrotoxic nephritis].
Kakuta, S, 1993
)
0.29
" Selective PAF, TXA2 and 5HT antagonists (WEB 2086, sulotroban and MCI-9042) clearly inhibited both the shape change and the aggregation induced by the appropriate agonist; in each case the effect of the antagonist was to move the dose-response curve to the right."( Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Heptinstall, S; Lösche, W; Sanderson, HM; Vickers, J, 1996
)
0.56
" There was lack of a dose-response relationship at this concentration range (3."( Effects of the platelet-activating factor receptor antagonist WEB 2086 on whole blood coagulation and fibrinolysis in a thromboelastography assay.
Dambisya, YM; Hussaini, IM; Lee, TL, 1995
)
0.53
" Addition of WEB 2086 to bovine platelets in vitro induced a rightward shift in the dose-response curve to PAF."( Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva, MB; David, JL; Dessy, C; Gustin, P; Herion, F; Lekeux, P; Raskinet, R, 1996
)
0.92
" Dose-response curves to noradrenaline-induced vasoconstriction were performed before and after continuous infusions of two different PAF-receptor antagonists (WEB 2086 and yangambin) and of the phospholipase A2 inhibitor mepacrine."( Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney.
Aimbire, F; Cailleaux, S; Cordeiro, RS; Lopes-Martins, RA; Tibiriçá, E, 1999
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
organosulfur heterocyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency31.62280.012610.691788.5700AID887
SMAD family member 2Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346859
progesterone receptorHomo sapiens (human)Potency10.59090.000417.946075.1148AID1346784
farnesoid X nuclear receptorHomo sapiens (human)Potency16.78420.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.49010.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.91450.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency14.95890.023723.228263.5986AID743222
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency7.49780.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.10930.00430.75777.8000AID154442; AID157717; AID165614
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)Ki0.06780.00040.33863.2500AID154449; AID157897; AID157902
Platelet-activating factor receptorHomo sapiens (human)IC50 (µMol)0.17350.00030.63183.7000AID157738; AID157741; AID161084; AID59351
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (152)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (97)

Assay IDTitleYearJournalArticle
AID60983Inhibition of PAF-induced platelet aggregation in whole blood obtained after 4 hr from dog injected with an intravenous dose of 1 mg/Kg of compound1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID112424Dosage required to inhibit PAF-induced mortality in mice by 50% through intravenous route1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID77757%inhibition of guinea pig bronchospasm at a peroral dose of 10 mg/kg and after 2 hr followed by iv challenge with 0.4 micro g/kg of PAF1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
AID154440Dose required to inhibit PAF-induced mortality by 50% in mice1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID115574Percentage of inhibition by the compound against PAF-induced mortality in mice 3 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID76267Inhibition of PAF-induced bronchoconstriction in the guinea pig, (1 mg/kg) intravenously at one-minute pretreatment time1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID77876Compound tested for its %inhibition of guinea pig bronchospasm at a peroral dose of 10 mg/kg and after 2 hr followed by iv challenge with 0.4 micro g/kg of histamine.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
AID161084Displacement of [3H]PAF from PAF receptor of human platelet membranes1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
AID167806Concentration required to inhibit PAF-induced maximum aggregation by 50%2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
AID78323In vivo inhibition against PAF-induced bronchoconstriction in guinea pig at 1 mg/kg dose upon peroral administration after one-minute pre-treatment time.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
AID132753In vivo antagonist activity against PAF-Induced paw edema in the mouse1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
AID115575Percentage of inhibition by the compound against PAF-induced mortality in mice 5 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID113143Ability to protect mice from lethal effects of an injection of PAF in vivo.1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
AID89260Concentration required to cause 50% inhibition of platelet activating factor (PAF)-induced platelet aggregation of human platelet rich plasma when challenged with 25 nM PAF.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
AID59351PAF-antagonist activity determined in dog platelets by PAF-binding assay1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID76841In vivo inhibitory dose against PAF-induced bronchoconstriction in guinea pig upon intravenous administration after one-minute pre-treatment time.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
AID154442Inhibition of PAF-induced platelet aggregation1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID225174Tested for dose required to inhibit endotoxin-induced mortality by 50 % when administered perorally in endotoxin-induced mortality (EIM) mice1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID157718Dose required to inhibit PAF-induced hypotension (PAF-Antagonistic activity) in normotensive rats by 50%.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
AID77002PAF-induced capillary permeability changes are studied in guinea pig test, after intravenous administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID77001PAF-induced capillary permeability changes are studied in guinea pig skin test, after peroral administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID182806Dose required to reduce the lowering of the arterial blood pressure caused by PAF by 50% after intravenous administration in rats1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID60984Inhibition of PAF-induced platelet aggregation in whole blood obtained after 6 hr from dog injected with an intravenous dose of 1 mg/Kg of compound1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID76843In vivo inhibitory dose against PAF-induced bronchoconstriction in guinea pig upon peroral administration after one-minute pretreatment time1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
AID92393In vitro antagonist activity, determined by 50% inhibition of PAF-induced platelet aggregation of human platelet rich plasma when challenged with PAF1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
AID77728Ability to prevent PAF-induced bronchoconstriction in guinea pig 6 hr following 50 mg/kg p.o. administration.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76854Inhibition of PAF-induced bronchoconstriction in guinea pig after oral administration after two-hour pretreatment time1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID154449Antagonist activity against platelet activating factor (PAF) receptor in rabbit platelet membranes using [3H]C18-PAF as radioligand1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
AID77758Compound tested for its %inhibition of guinea pig bronchospasm at a peroral dose of 10 mg/kg and after 2 hr followed by iv challenge with 0.4 micro g/kg of PAF.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
AID165480Concentration required to inhibit PAF-induced maximum platelet aggregation in rabbit platelet-rich plasma1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID225173Tested for dose required to inhibit endotoxin-induced mortality by 50 % when administered intravenously in endotoxin-induced mortality (EIM) mice1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID157738Inhibition of [3H]PAF binding to dog platelets.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID679258TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells2002European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Aug, Volume: 16, Issue:3
Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
AID157901Competitive inhibitory against Platelet activating factor receptor in rabbit-washed platelets was measured as pKb1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.
AID76987Inhibition of PAF-induced bronchoconstriction in the guinea pig after intravenous administration1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID183449Tested for dose required to inhibit endotoxin-induced mortality by 50 % when administered intravenously in endotoxin-induced mortality (EIM) rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID157715Oral dose required to inhibit PAF-induced mortality (PAF-Antagonistic activity)in mice by 50%.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
AID221553Tested for dose required to inhibit antigen-induced mortality by 50 % when administered perorally in active anaphylactic shock (AAS) mice1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID115576Percentage of inhibition by the compound against PAF-induced mortality in mice 7 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID165614In vitro inhibition of PAF-induced aggregation of rabbit washed platelets.1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
AID76269Inhibition of PAF-induced bronchoconstriction in the guinea pig after 1 mg/kg p.o. administration two hours prior to challenge.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
AID183140PAF-induced capillary permeability changes are studied in rat skin test, after peroral administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID157897In vitro intrinsic binding affinity at platelet activating factor receptor using rabbit platelet membranes1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.
AID77730Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered at a dose of 1 mg/kg intravenously1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID157717Concentration tested in vitro to inhibit PAF-induced maximum aggregation (PAF-Antagonistic activity) by 50%.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
(Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
AID157902Competitive inhibition of Platelet activating factor receptor in rabbit-washed platelets1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.
AID176972In vivo antagonist activity for PAF-Induced cutaneous vascular permeability in the rat1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
AID112425Dosage required to inhibit PAF-induced mortality in mice by 50% through oral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID183451Tested for dose required to inhibit endotoxin-induced mortality by 50 % when administered perorally in endotoxin-induced mortality (EIM) rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID221551Tested for dose required to inhibit antigen-induced mortality by 50 % when administered intravenously in active anaphylactic shock (AAS) mice1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID77727Ability to prevent PAF-induced bronchoconstriction in guinea pig 2 hr after administration (50 mg/kg perorally)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID154443Intravenous dose required to reduce the arterial blood pressure caused by PAF by 50% in rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists.
AID157741In vitro for platelet activating factor receptor antagonist activity in a binding assay using washed whole dog platelets.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
AID104509Dose required to reduce the lowering of the arterial blood pressure caused by PAF by 50 %.2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
AID678898TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse2002European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Aug, Volume: 16, Issue:3
Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
AID76993Inhibition of PAF-induced bronchoconstriction in guinea pig 2 hr after p.o. administration.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID76658Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered intravenously1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID224180Concentration required to inhibit PAF (5*10e-8 M) induced platelet aggregation in rabbit platelet rich plasma(PRP) by 50%1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
AID183139PAF-induced capillary permeability changes are studied in rat skin test, after intravenous administration of the compound1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346403Human PAF receptor (Platelet-activating factor receptor)2001The Journal of biological chemistry, Nov-16, Volume: 276, Issue:46
Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1991The Journal of biological chemistry, Oct-25, Volume: 266, Issue:30
Molecular cloning and expression of platelet-activating factor receptor from human leukocytes.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1995Journal of immunological methods, Oct-26, Volume: 186, Issue:2
A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1993Biochemical and biophysical research communications, Jan-15, Volume: 190, Issue:1
Evidence for the presence of specific high affinity cytosolic binding sites for platelet-activating factor in human neutrophils.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1996The Journal of biological chemistry, Sep-20, Volume: 271, Issue:38
Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (580)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (9.48)18.7374
1990's429 (73.97)18.2507
2000's61 (10.52)29.6817
2010's27 (4.66)24.3611
2020's8 (1.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.14 (24.57)
Research Supply Index6.41 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (1.33%)5.53%
Reviews10 (1.67%)6.00%
Case Studies1 (0.17%)4.05%
Observational0 (0.00%)0.25%
Other581 (96.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]